Target molecules for anti-angiogenic therapy: From basic research to clinical trials

Critical Reviews in Oncology/Hematology

Volumn 34, Issue 2, 2000, Pages 89-110

  Hagedorn, Martin ^a   Bikfalvi, Andreas ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Angiogenesis; Angiogenesis inhibitor; Clinical trial; Endothelial cell

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 4 DEDIMETHYLAMINOSANCYCLINE; AE 941; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOSTATIN; ANGIOZYME; ANTINEOPLASTIC AGENT; BENFLURALIN; BMS 2752291; CARBOXYAMIDOIMIDAZOLE; CGS 27023A; CILENGITIDE; CM 101; COMBRETASTATIN A4; CT 2584; CYTOKINE; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; FLAVOPIRIDOL; FUMAGILLOL CHLOROACETYLCARBAMATE; IM 862; INTEGRIN; INTERLEUKIN 12; LEFLUNOMIDE; MARIMASTAT; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY LM 609; PACLITAXEL; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; PRINOMASTAT; PURPURIN; RHUMAB ANTI VEGF; SQUALAMINE; SURADISTA; TANOMASTAT; THALIDOMID; THROMBOCYTE FACTOR 4; THROMBOSPONDIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB; ZD 0101; ZK 22584;

ANGIOGENESIS; ANIMAL MODEL; CANCER; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG TARGETING; ENDOTHELIUM CELL; EYE DISEASE; HUMAN; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOPHYSIOLOGY; REVIEW; RHEUMATOID ARTHRITIS;

ANGIOGENESIS INHIBITORS; ANIMALS; CLINICAL TRIALS; ENDOTHELIUM, VASCULAR; GROWTH SUBSTANCES; HUMANS; RESEARCH DESIGN;

EID: 0034054325     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(00)00056-1     Document Type: Article

References (222)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1(1):1995;27-31.
2. Risau W. Mechanisms of angiogenesis. Nature. 386(6626):1997;671-674.
3. Hanahan D. Signaling vascular morphogenesis and maintenance [comment]. Science. 277(5322):1997;48-50.
4. Rivard A., Isner J.M. Angiogenesis and vasculogenesis in treatment of cardiovascular disease. Mol. Med. 4(7):1998;429-440.
5. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285(21):1971;1182-1186.
6. Belotti D., Vergani V., Drudis T. et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity [In Process Citation]. Clin. Cancer Res. 2(11):1996;1843-1849.
7. D'Amato R.J., Loughnan M.S., Flynn E. et al. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA. 91(9):1994;4082-4085.
8. Ezekowitz R.A., Mulliken J.B., Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy [see comments] [published errata appear in N Engl J Med Jan 27;330(4):300 and 1995 Aug 31;333(9):595-6]. N. Engl. J. Med. 326(22):1992;1456-1463.
9. Huang X., Molema G., King S. et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature [see comments]. Science. 275(5299):1997;547-550.
10. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model [see comments]. Science. 279(5349):1998;377-380.
11. Leung D.W., Cachianes G., Kuang W.J. et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246(4935):1989;1306-1309.
12. Keck P.J., Hauser S.D., Krivi G. et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 246(4935):1989;1309-1312.
13. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18(1):1997;4-25.
14. Soker S., Gollamudi-Payne S., Fidder H. et al. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7- encoded domain of VEGF165. J. Biol. Chem. 272(50):1997;31582-31588.
15. Olofsson B., Pajusola K., Kaipainen A. et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl. Acad. Sci. USA. 93(6):1996;2576-2581.
16. Joukov V., Pajusola K., Kaipainen A. et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15(7):1996;1751.
17. Achen M.G., Jeltsch M., Kukk E. et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl. Acad. Sci. USA. 95(2):1998;548-553.
18. Yamada Y., Nezu J., Shimane M. et al. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics. 42(3):1997;483-488.
19. Ogawa S., Oku A., Sawano A. et al. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J. Biol. Chem. 273(47):1998;31273-31282.
20. Carmeliet P., Ferreira V., Breier G. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 380(6573):1996;435-439.
21. Gerber H.P., Hillan K.J., Ryan A.M. et al. VEGF is required for growth and survival in neonatal mice. Development. 126(6):1999;1149-1159.
22. Salven P., Ruotsalainen T., Mattson K. et al. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int. J. Cancer. 79(2):1998;144-146.
23. Eppenberger U., Kueng W., Schlaeppi J.M. et al. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J. Clin. Oncol. 16(9):1998;3129-3136.
24. Kim K.J., Li B., Winer J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 362(6423):1993;841-844.
25. Borgstrom P., Bourdon M.A., Hillan K.J. et al. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate. 35(1):1998;1-10.
26. Lin Y.S., Nguyen C., Mendoza J.L. et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J. Pharmacol. Exp. Ther. 288(1):1999;371-378.
27. Presta L.G., Chen H., O'Connor S.J. et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57(20):1997;4593-4599.
28. Arora N., Masood R., Zheng T. et al. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res. 59(1):1999;183-188.
29. Hiratsuka S., Minowa O., Kuno J. et al. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. USA. 95(16):1998;9349-9354.
30. Kendall R.L., Wang G., Thomas K.A. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun. 226(2):1996;324-328.
31. Goldman C.K., Kendall R.L., Cabrera G. et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc. Natl. Acad. Sci. USA. 95(15):1998;8795-8800.
32. Aiello L.P., Avery R.L., Arrigg P.G. et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders [see comments]. N. Engl. J. Med. 331(22):1994;1480-1487.
33. D'Amore P.A. Mechanisms of retinal and choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 35(12):1994;3974-3979.
34. Aiello L.P., Pierce E.A., Foley E.D. et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA. 92(23):1995;10457-10461.
35. Fairbrother W.J., Christinger H.W., Cochran A.G. et al. Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site. Biochemistry. 37(51):1998;17754-17764.
36. Soker S., Takashima S., Miao H.Q. et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform- specific receptor for vascular endothelial growth factor. Cell. 92(6):1998;735-745.
37. Piossek C., Schneider-Mergener J., Schirner M. et al. Vascular endothelial growth factor (VEGF) receptor II-derived peptides inhibit VEGF. J. Biol. Chem. 274(9):1999;5612-5619.
38. Sun L., Tran N., Tang F. et al. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J. Med. Chem. 41(14):1998;2588-2603.
39. Fong T.A., Shawver L.K., Sun L. et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59(1):1999;99-106.
40. SUGEN, http://www.sugen.com (Website Press releases 09/11/1998), 1998.
41. Dumont D.J., Yamaguchi T.P., Conlon R.A. et al. Tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. Oncogene. 7(8):1992;1471-1480.
42. Iwama A., Hamaguchi I., Hashiyama M. et al. Molecular cloning and characterization of mouse TIE and TEK receptor tyrosine kinase genes and their expression in hematopoietic stem cells. Biochem. Biophys. Res. Commun. 195(1):1993;301-309.
43. Partanen J., Armstrong E., Makela T.P. et al. A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol. Cell. Biol. 12(4):1992;1698-1707.
44. Schnurch H., Risau W. Expression of tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage. Development. 119(3):1993;957-968.
45. Sato T.N., Tozawa Y., Deutsch U. et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 376(6535):1995;70-74.
46. Puri M.C., Rossant J., Alitalo K. et al. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J. 14(23):1995;5884-5891.
47. Dumont D.J., Gradwohl G., Fong G.H. et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev. 8(16):1994;1897-1909.
48. Vikkula M., Boon L.M., Carraway K.L. III et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2 [see comments]. Cell. 87(7):1996;1181-1190.
49. Korhonen J., Partanen J., Armstrong E. et al. Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during neovascularization. Blood. 80(10):1992;2548-2555.
50. Wong A.L., Haroon Z.A., Werner S. et al. Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ. Res. 81(4):1997;567-574.
51. Peters K.G., Coogan A., Berry D. et al. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br. J. Cancer. 77(1):1998;51-56.
52. Stratmann A., Risau W., Plate K.H. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis [see comments]. Am. J. Pathol. 153(5):1998;1459-1466.
53. Lin P., Polverini P., Dewhirst M. et al. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J. Clin. Invest. 100(8):1997;2072-2078.
54. Lin P., Buxton J.A., Acheson A. et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc. Natl. Acad. Sci. USA. 95(15):1998;8829-8834.
55. Davis S., Aldrich T.H., Jones P.F. et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning [see comments]. Cell. 87(7):1996;1161-1169.
56. Suri C., Jones P.F., Patan S. et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis [see comments]. Cell. 87(7):1996;1171-1180.
57. Maisonpierre P.C., Suri C., Jones P.F. et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis [see comments]. Science. 277(5322):1997;55-60.
58. Valenzuela D.M., Griffiths J.A., Rojas J. et al. Angiopoietins 3 and 4: diverging gene counterparts in mice and humans [In Process Citation]. Proc. Natl. Acad. Sci. USA. 96(5):1999;1904-1909.
59. Gospodarowicz D. Purification of a fibroblast growth factor from bovine pituitary. J. Biol. Chem. 250(7):1975;2515-2520.
60. Maciag T., Mehlman T., Friesel R. et al. Heparin binds endothelial cell growth factor, the principal endothelial cell mitogen in bovine brain. Science. 225(4665):1984;932-935.
61. Shing Y., Folkman J., Sullivan R. et al. Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science. 223(4642):1984;1296-1299.
62. Prats H., Kaghad M., Prats A.C. et al. High molecular mass forms of basic fibroblast growth factor are initiated by alternative CUG codons. Proc. Natl. Acad. Sci. USA. 86(6):1989;1836-1840.
63. Seghezzi G., Patel S., Ren C.J. et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J. Cell. Biol. 141(7):1998;1659-1673.
64. Montesano R., Vassalli J.D., Baird A. et al. Basic fibroblast growth factor induces angiogenesis in vitro. Proc. Natl. Acad. Sci. USA. 83(19):1986;7297-7301.
65. Karsan A., Yee E., Poirier G.G. et al. Fibroblast growth factor-2 inhibits endothelial cell apoptosis by Bcl-2- dependent and independent mechanisms. Am. J. Pathol. 151(6):1997;1775-1784.
66. Hori A., Sasada R., Matsutani E. et al. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res. 51(22):1991;6180-6184.
67. Ueno H., Li J.J., Masuda S. et al. Adenovirus-mediated expression of the secreted form of basic fibroblast growth factor (FGF-2) induces cellular proliferation and angiogenesis in vivo. Arterioscler. Thromb. Vasc. Biol. 17(11):1997;2453-2460.
68. Ortega S., Ittmann M., Tsang S.H. et al. Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2. Proc. Natl. Acad. Sci. USA. 95(10):1998;5672-5677.
69. Friesel R.E., Maciag T. Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J. 9(10):1995;919-925.
70. Panek R.L., Lu G.H., Dahring T.K. et al. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase. J. Pharmacol. Exp. Ther. 286(1):1998;569-577.
71. Mohammadi M., Froum S., Hamby J.M. et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 17(20):1998;5896-5904.
72. Perollet C., Han Z.C., Savona C. et al. Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood. 91(9):1998;3289-3299.
73. Strieter R.M., Polverini P.J., Kunkel S.L. et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 270(45):1995;27348-27357.
74. Strieter R.M., Polverini P.J., Arenberg D.A. et al. Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J. Leukoc. Biol. 57(5):1995;752-762.
75. Arenberg D.A., Polverini P.J., Kunkel S.L. et al. In vitro and in vivo systems to assess role of C-X-C chemokines in regulation of angiogenesis. Methods Enzymol. 288:1997;190-220.
76. Taylor S., Folkman J. Protamine is an inhibitor of angiogenesis. Nature. 297(5864):1982;307-312.
77. Maione T.E., Gray G.S., Petro J. et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science. 247(4938):1990;77-79.
78. Gengrinovitch S., Greenberg S.M., Cohen T. et al. Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms. J. Biol. Chem. 270(25):1995;15059-15065.
79. Jouan V, Canron X, Alemany M, et al. Inhibition of in vitro angiogenesis by platelet factor 4 derived peptides and mecanism of action, Blood, 1999;94(3):984-93.
80. Maione T.E., Gray G.S., Hunt A.J. et al. Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity. Cancer Res. 51(8):1991;2077-2083.
81. Kolber D.L., Knisely T.L., Maione T.E. Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. J. Natl. Cancer Inst. 87(4):1995;304-309.
82. Tanaka T., Manome Y., Wen P. et al. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat. Med. 3(4):1997;437-442.
83. Hansell P., Olofsson M., Maione T.E. et al. Differences in binding of platelet factor 4 to vascular endothelium in vivo and endothelial cells in vitro. Acta Physiol. Scand. 154(4):1995;449-459.
84. Hansell P., Maione T.E., Borgstrom P. Selective binding of platelet factor 4 to regions of active angiogenesis in vivo. Am. J. Physiol. 269(3 (Part 2)):1995;829-836.
85. Borgstrom P., Discipio R., Maione T.E. Recombinant platelet factor 4, an angiogenic marker for human breast carcinoma. Anticancer Res. 18(6A):1998;4035-4041.
86. Belman N., Bonnem E.M., Harvey H.A. et al. Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced colorectal carcinoma. Invest. New Drugs. 14(4):1996;387-389.
87. Stearns M.E., Rhim J., Wang M. Interleukin 10 (IL-10) inhibition of primary human prostate cell- induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)- 2/MMP-9 secretion. Clin. Cancer Res. 5(1):1999;189-196.
88. Luca M., Huang S., Gershenwald J.E. et al. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am. J. Pathol. 151(4):1997;1105-1113.
89. Miller L.J., Kurtzman S.H., Wang Y. et al. Expression of interleukin-8 receptors on tumor cells and vascular endothelial cells in human breast cancer tissue. Anticancer Res. 18(1A):1998;77-81.
90. Voest E.E., Kenyon B.M., O'Reilly M.S. et al. Inhibition of angiogenesis in vivo by interleukin 12 [see comments]. J. Natl. Cancer Inst. 87(8):1995;581-596.
91. Sgadari C., Angiolillo A.L., Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood. 87(9):1996;3877-3882.
92. Strieter R.M., Kunkel S.L., Arenberg D.A. et al. Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem. Biophys. Res. Commun. 210(1):1995;51-57.
93. Dias S., Boyd R., Balkwill F. IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int. J. Cancer. 78(3):1998;361-365.
94. Vallee B.L., Riordan J.F. Organogenesis and angiogenin. Cell. Mol. Life Sci. 53(10):1997;803-815.
95. Fett J.W., Strydom D.J., Lobb R.R. et al. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry. 24(20):1985;5480-5486.
96. Hu G.F. Limited proteolysis of angiogenin by elastase is regulated by plasminogen. J. Protein Chem. 16(7):1997;669-679.
97. Shimoyama S., Gansauge F., Gansauge S. et al. Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness. Cancer Res. 56(12):1996;2703-2706.
98. Hu G.F., Strydom D.J., Fett J.W. et al. Actin is a binding protein for angiogenin. Proc. Natl. Acad. Sci. USA. 90(4):1993;1217-1221.
99. Hu G., Riordan J.F., Vallee B.L. Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities. Proc. Natl. Acad. Sci. USA. 91(25):1994;12096-12100.
100. Hu G.F., Riordan J.F., Vallee B.L. A putative angiogenin receptor in angiogenin-responsive human endothelial cells. Proc. Natl. Acad. Sci. USA. 94(6):1997;2204-2209.
101. Olson K.A., French T.C., Vallee B.L. et al. A monoclonal antibody to human angiogenin suppresses tumor growth in athymic mice. Cancer Res. 54(17):1994;4576-4579.
102. Piccoli R., Olson K.A., Vallee B.L. et al. Chimeric anti-angiogenin antibody cAb 26-2F inhibits the formation of human breast cancer xenografts in athymic mice. Proc. Natl. Acad. Sci. USA. 95(8):1998;4579-4583.
103. Nobile V., Russo N., Hu G. et al. Inhibition of human angiogenin by DNA aptamers: nuclear colocalization of an angiogenin-inhibitor complex. Biochemistry. 37(19):1998;6857-6863.
104. Hu G.F. Neomycin inhibits angiogenin-induced angiogenesis. Proc. Natl. Acad. Sci. USA. 95(17):1998;9791-9795.
105. O'Reilly M.S., Holmgren L., Shing Y. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma [see comments]. Cell. 79(2):1994;315-328.
106. Lucas R., Holmgren L., Garcia I. et al. Multiple forms of angiostatin induce apoptosis in endothelial cells [In Process Citation]. Blood. 92(12):1998;4730-4741.
107. O'Reilly M.S., Holmgren L., Chen C. et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2(6):1996;689-692.
108. Sim B.K., O'Reilly M.S., Liang H. et al. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res. 57(7):1997;1329-1334.
109. O'Reilly M.S., Boehm T., Shing Y. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88(2):1997;277-285.
110. Dhanabal M., Ramchandran R., Volk R. et al. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res. 59(1):1999;189-197.
111. Hohenester E., Sasaki T., Olsen B.R. et al. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J. 17(6):1998;1656-1664.
112. Ramchandran R., Dhanabal M., Volk R. et al. Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin [In Process Citation]. Biochem. Biophys. Res. Commun. 255(3):1999;735-739.
113. Pike S.E., Yao L., Jones K.D. et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth [In Process Citation]. J. Exp. Med. 188(12):1998;2349-2356.
114. Struman I., Bentzien F., Lee H. et al. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis [In Process Citation]. Proc. Natl. Acad. Sci. USA. 96(4):1999;1246-1251.
115. Lawler J.W., Slayter H.S., Coligan J.E. Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. J. Biol. Chem. 253(23):1978;8609-8616.
116. Taraboletti G., Roberts D., Liotta L.A. et al. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J. Cell. Biol. 111(2):1990;765-772.
117. Good D.J., Polverini P.J., Rastinejad F. et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA. 87(17):1990;6624-6628.
118. Dameron K.M., Volpert O.V., Tainsky M.A. et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 265(5178):1994;1582-1584.
119. Grossfeld G.D., Ginsberg D.A., Stein J.P. et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J. Natl. Cancer Inst. 89(3):1997;219-227.
120. Bleuel K., Popp S., Fusenig N.E. et al. Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization [In Process Citation]. Proc. Natl. Acad. Sci. USA. 96(5):1999;2065-2070.
121. Suzuma K., Takagi H., Otani A. et al. Expression of thrombospondin-1 in ischemia-induced retinal neovascularization. Am. J. Pathol. 154(2):1999;343-354.
122. Tolsma S.S., Volpert O.V., Good D.J. et al. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J. Cell Biol. 122(2):1993;497-511.
123. Dawson D.W., Volpert O.V., Pearce S.F. et al. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol. Pharmacol. 55(2):1999;332-338.
124. Brooks P.C., Clark R.A., Cheresh D.A. Requirement of vascular integrin αvβ 3 for angiogenesis. Science. 264(5158):1994;569-571.
125. Friedlander M., Theesfeld C.L., Sugita M. et al. Involvement of integrins αvβ3 and αvβ5 in ocular neovascular diseases. Proc. Natl. Acad. Sci. USA. 93(18):1996;9764-9769.
126. Brooks P.C., Stromblad S., Klemke R. et al. Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin [see comments]. J. Clin. Invest. 96(4):1995;1815-1822.
127. Friedlander M., Brooks P.C., Shaffer R.W. et al. Definition of two angiogenic pathways by distinct α v integrins. Science. 270(5241):1995;1500-1502.
128. Soldi R., Mitola S., Strasly M. et al. Role of αvβ3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J. 18(4):1999;882-892.
129. Brooks P.C., Montgomery A.M., Rosenfeld M. et al. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 79(7):1994;1157-1164.
130. Yeh C.H., Peng H.C., Huang T.F. Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin αvβ3 antagonist and inducing apoptosis. Blood. 92(9):1998;3268-3276.
131. Luna J., Tobe T., Mousa S.A. et al. Antagonists of integrin αvβ3 inhibit retinal neovascularization in a murine model. Lab. Invest. 75(4):1996;563-573.
132. Hammes H.P., Brownlee M., Jonczyk A. et al. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat. Med. 2(5):1996;529-533.
133. Srivatsa S.S., Fitzpatrick L.A., Tsao P.W. et al. Selective αvβ3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin αvβ3 and osteopontin expression during neointima formation. Cardiovasc. Res. 36(3):1997;408-428.
134. Liaw L., Lindner V., Schwartz S.M. et al. Osteopontin and β 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. Circ. Res. 77(4):1995;665-672.
135. Lawler J., Weinstein R., Hynes R.O. Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors. J. Cell Biol. 107((6 Part 1)):1988;2351-2361.
136. Rusnati M., Tanghetti E., Dell'Era P. et al. αvβ3 Integrin mediates the cell-adhesive capacity and biological activity of basic fibroblast growth factor (FGF-2) in cultured endothelial cells. Mol. Biol. Cell. 8(12):1997;2449-2461.
137. Brooks P.C., Stromblad S., Sanders L.C. et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell. 85(5):1996;683-693.
138. Wu H., Beuerlein G., Nie Y. et al. Stepwise in vitro affinity maturation of Vitaxin, an αvβ3-specific humanized mAb. Proc. Natl. Acad. Sci. USA. 95(11):1998;6037-6042.
139. Gutheil J. Phase I study of vitaxin, an anti-angiogenic humanized monoclonal antibody to vascular integrin αvβ3. in 34th Annual Meeting of the American Society of Clinical Oncology. 1998. Los Angeles, CA.
140. Koivunen E., Wang B., Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (NY). 13(3):1995;265-270.
141. Pasqualini R., Koivunen E., Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands [see comments]. Nat. Biotechnol. 15(6):1997;542-546.
142. Gomis-Ruth F.X., Maskos K., Betz M. et al. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature. 389(6646):1997;77-81.
143. Kossakowska A.E., Huchcroft S.A., Urbanski S.J. et al. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. Br. J. Cancer. 73(11):1996;1401-1408.
144. Gohji K., Fujimoto N., Fujii A. et al. Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res. 56(14):1996;3196-3198.
145. Chenard M.P., O'Siorain L., Shering S. et al. High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int. J. Cancer. 69(6):1996;448-451.
146. Murray G.I., Duncan M.E., O'Neil P. et al. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat. Med. 2(4):1996;461-462.
147. Kim J., Yu W., Kovalski K. et al. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell. 94(3):1998;353-362.
148. Park J.E., Keller G.A., Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell. 4(12):1993;1317-1326.
149. Wang H., Keiser J.A. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. Circ. Res. 83(8):1998;832-840.
150. Brooks P.C., Silletti S., von Schalscha T.L. et al. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell. 92(3):1998;391-400.
151. Patterson B.C., Sang Q.A. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J. Biol. Chem. 272(46):1997;28823-28825.
152. Cornelius L.A., Nehring L.C., Harding E. et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J. Immunol. 161(12):1998;6845-6852.
153. Sang Q.X. Complex role of matrix metalloproteinases in angiogenesis. Cell. Res. 8(3):1998;171-177.
154. Wojtowicz-Praga S., Torri J., Johnson M. et al. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncol. 16(6):1998;2150-2156.
155. Collier MA, Yuen GJ, Bansal SK, et al. A Phase I study of the matrix metalloproteinase (MMP) inhibitor AG3340 given in single doses to healthy volunteers (Meeting abstract). in Proc Annu Meet Am Assoc Cancer Res. 1997.
156. Landau B.J., Kwaan H.C., Verrusio E.N. et al. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors. Cancer Res. 54(4):1994;1105-1108.
157. Grondahl-Hansen J., Christensen I.J., Rosenquist C. et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 53(11):1993;2513-2521.
158. Soff G.A., Sanderowitz J., Gately S. et al. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J. Clin. Invest. 96(6):1995;2593-2600.
159. Lee H., Struman I., Clapp C. et al. Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression. Endocrinology. 139(9):1998;3696-3703.
160. Bajou K., Noel A., Gerard R.D. et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 4(8):1998;923-928.
161. Montesano R., Pepper M.S., Mohle-Steinlein U. et al. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell. 62(3):1990;435-445.
162. Yihai C, Renhai C. Angiogenesis inhibited by drinking tea, Nature 1999;398(6726):381.
163. Folkman J., Haudenschild C. Angiogenesis in vitro. Nature. 288(5791):1980;551-556.
164. Brown K.J., Maynes S.F., Bezos A. et al. A novel in vitro assay for human angiogenesis. Lab. Invest. 75(4):1996;539-555.
165. Nicosia R.F., Tchao R., Leighton J. Histotypic angiogenesis in vitro: light microscopic, ultrastructural, and radioautographic studies. In Vitro. 18(6):1982;538-549.
166. Nicosia R.F., Lin Y.J., Hazelton D. et al. Endogenous regulation of angiogenesis in the rat aorta model. Role of vascular endothelial growth factor. Am. J. Pathol. 151(5):1997;1379-1386.
167. Kusaka M., Sudo K., Fujita T. et al. Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem. Biophys. Res. Commun. 174(3):1991;1070-1076.
168. Gimbrone MA, Jr., Cotran RS, Leapman SB, et al. Tumor growth and neovascularization: an experimental model using the rabbit cornea, J Natl Cancer Inst, 1974;52(2):413-27.
169. Fournier G.A., Lutty G.A., Watt S. et al. A corneal micropocket assay for angiogenesis in the rat eye. Invest. Ophthalmol. Vis. Sci. 21(2):1981;351-354.
170. Muthukkaruppan V., Auerbach R. Angiogenesis in the mouse cornea. Science. 205(4413):1979;1416-1418.
171. Lichtenberg J., Hansen C.A., Skak-Nielsen T. et al. The rat subcutaneous air sac model: a new and simple method for in vivo screening of antiangiogenesis. Pharmacol. Toxicol. 81(6):1997;280-284.
172. Rofstad E.K. Orthotopic human melanoma xenograft model systems for studies of tumour angiogenesis, pathophysiology, treatment sensitivity and metastatic pattern. Br. J. Cancer. 70(5):1994;804-812.
173. Smith L., Wesolowski E., McLellan A. et al. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 35(1):1994;101-111.
174. Thompson W.D., Harvey J.A., Kazmi M.A. et al. Fibrinolysis and angiogenesis in wound healing. J. Pathol. 165(4):1991;311-318.
175. Passaniti A., Taylor R.M., Pili R. et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest. 67(4):1992;519-528.
176. Hanahan D. Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature. 315(6015):1985;115-122.
177. Knighton D., Ausprunk D., Tapper D. et al. Avascular and vascular phases of tumour growth in the chick embryo. Br. J. Cancer. 35(3):1977;347-356.
178. Nguyen M., Shing Y., Folkman J. Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane. Microvasc. Res. 47(1):1994;31-40.
179. Auerbach R., Kubai L., Knighton D. et al. A simple procedure for the long-term cultivation of chicken embryos. Dev. Biol. 41(2):1974;391-394.
180. Suri C., McClain J., Thurston G. et al. Increased vascularization in mice overexpressing angiopoietin-1. Science. 282(5388):1998;468-471.
181. Ferrara N., Carver-Moore K., Chen H. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 380(6573):1996;439-442.
182. Fong G.H., Rossant J., Gertsenstein M. et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 376(6535):1995;66-70.
183. Shalaby F., Rossant J., Yamaguchi T.P. et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 376(6535):1995;62-66.
184. Dumont D.J., Jussila L., Taipale J. et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science. 282(5390):1998;946-949.
185. Bader B.L., Rayburn H., Crowley D. et al. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all α v integrins. Cell. 95(4):1998;507-519.
186. Dickson M.C., Martin J.S., Cousins F.M. et al. Defective haematopoiesis and vasculogenesis in transforming growth factor-β 1 knock out mice. Development. 121(6):1995;1845-1854.
187. Lindahl P., Johansson B.R., Leveen P. et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 277(5323):1997;242-245.
188. O'Reilly M.S., Holmgren L., Shing Y. et al. Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold. Spring. Harb. Symp. Quant. Biol. 59:1994;471-482.
189. Koivunen E., Arap W., Valtanen H. et al. Tumor targeting with a selective gelatinase inhibitor [In Process Citation]. Nat. Biotechnol. 17(8):1999;768-774.
190. Carron C.P., Meyer D.M., Pegg J.A. et al. A peptidomimetic antagonist of the integrin α(v)β3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer. Res. 58(9):1998;1930-1935.
191. Prewett M, Li Y, Huber J, et al. VEGF receptor blockade by an anti-Flk1 monoclonal antibody inhibits tumor associated angiogenesis and tumor growth. in AACR 90th Annual Meeting, Philadelphia, PA, USA, April 10-14. 1999.
192. Taraboletti G., Belotti D., Borsotti P. et al. The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. Cell. Growth. Differ. 8(4):1997;471-479.
193. Itoh T., Tanioka M., Yoshida H. et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer. Res. 58(5):1998;1048-1051.
194. Wilson C.L., Heppner K.J., Labosky P.A. et al. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl. Acad. Sci. U. S. A. 94(4):1997;1402-1407.
195. Nwomeh B.C., Liang H.X., Cohen I.K. et al. MMP-8 is the predominant collagenase in healing wounds and nonhealing ulcers. J. Surg. Res. 81(2):1999;189-195.
196. Vu T.H., Shipley J.M., Bergers G. et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 93(3):1998;411-422.
197. Vaalamo M., Karjalainen-Lindsberg M.L., Puolakkainen P. et al. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am. J. Pathol. 152(4):1998;1005-1014.
198. Masson R., Lefebvre O., Noel A. et al. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J. Cell. Biol. 140(6):1998;1535-1541.
199. Dong Z., Kumar R., Yang X. et al. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell. 88(6):1997;801-810.
200. Puente X.S., Pendas A.M., Llano E. et al. Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer. Res. 56(5):1996;944-949.
201. Santos O., McDermott C.D., Daniels R.G. et al. Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases. Clin. Exp. Metastasis. 15(5):1997;499-508.
202. Seftor R.E., Seftor E.A., De Larco J.E. et al. Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin. Exp. Metastasis. 16(3):1998;217-225.
203. Latreille J, Laberge F, Rivière M, et al. Phase I/II clinical trials of escalating dose of Æ-941, an inhibitor of angiogenesis, in patients with refractory lung cancer. in AACR 90th Annual Meeting, Philadelphia, PA, USA, April 10-14. 1999.
204. MacPherson L.J., Bayburt E.K., Capparelli M.P. et al. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem. 40(16):1997;2525-2532.
205. Sandberg JA. Pharmacology and toxicology of an antiangiogenic ribozyme. in Angiogenesis: Novel Therapeutic Development. 1999. Boston, MA, USA: IBC.
206. Mang T.S., Allison R., Hewson G. et al. A phase II/III clinical study of tin ethyl etiopurpurin (Purlytin)- induced photodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer. Cancer. J. Sci. Am. 4(6):1998;378-384.
207. Kaplan M.J., Somers R.G., Greenberg R.H. et al. Photodynamic therapy in the management of metastatic cutaneous adenocarcinomas: case reports from phase 1/2 studies using tin ethyl etiopurpurin (SnET2). J. Surg. Oncol. 67(2):1998;121-125.
208. Shawver L.K., Schwartz D.P., Mann E. et al. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5- methylisoxazole-4-carboxamide. Clin. Cancer. Res. 3(7):1997;1167-1177.
209. Brusselbach S., Nettelbeck D.M., Sedlacek H.H. et al. Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells. Int. J. Cancer. 77(1):1998;146-152.
210. Ingber D., Fujita T., Kishimoto S. et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature. 348(6301):1990;555-557.
211. Griffith E.C., Su Z., Turk B.E. et al. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem. Biol. 4(6):1997;461-471.
212. Bauer K.S., Dixon S.C., Figg W.D. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem. Pharmacol. 55(11):1998;1827-1834.
213. Harris A.L. Clinical trials of anti-vascular agent group B Streptococcus toxin (CM101). Angiogenesis. 1(1):1997;36-37.
214. Dark G.G., Hill S.A., Prise V.E. et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer. Res. 57(10):1997;1829-1834.
215. Kohn E.C., Felder C.C., Jacobs W. et al. Structure-function analysis of signal and growth inhibition by carboxyamido-triazole, CAI. Cancer. Res. 54(4):1994;935-942.
216. McGarvey M.E., Tulpule A., Cai J. et al. Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma. Curr. Opin. Oncol. 10(5):1998;413-421.
217. Sills AK, Jr., Williams JI, Tyler BM, et al. Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature, Cancer Res 1998;58(13):2784-92.
218. Westerlund A., Hujanen E., Hoyhtya M. et al. Ovarian cancer cell invasion is inhibited by paclitaxel. Clin. Exp. Metastasis. 15(3):1997;318-328.
219. Majewski S., Marczak M., Szmurlo A. et al. Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo. J. Invest. Dermatol. 106(5):1996;1114-1118.
220. Chang E., Boyd A., Nelson C.C. et al. Successful treatment of infantile hemangiomas with interferon-α-2b. J. Pediatr. Hematol. Oncol. 19(3):1997;237-244.
221. Dinney C.P., Bielenberg D.R., Perrotte P. et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-α administration. Cancer. Res. 58(4):1998;808-814.
222. Jeltsch M., Kaipainen A., Joukov V. et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice [published erratum appears in Science Jul 25;277(5325):463]. Science,. 276. 1997(5317):1997;1423-1425.